Castle Biosciences' Gene Expression Tests Show Superior Survival Prediction in Melanoma Patients
核心洞察
A landmark study published in Nature Communications demonstrates that Castle Biosciences (搜索)' DecisionDx-UM (搜索) combined with PRAME (搜索) gene expression analysis outperforms next-generation sequencing-based mutation analysis in predicting survival outcomes for uveal melanoma (搜索) patients.
An independent expert consensus panel of ten melanoma (搜索) specialists unanimously endorsed DecisionDx-Melanoma (搜索) as a best-practice tool for managing cutaneous melanoma (搜索) patients, based on comprehensive review of 26 studies encompassing over 7,500 patients.
The DecisionDx-UM (搜索) and PRAME (搜索) combination provides superior predictions of both metastasis-free survival and overall survival by measuring gene activity from tumor cells and surrounding immune cells, offering a more comprehensive view of the tumor microenvironment.
Castle Biosciences (搜索) has achieved significant validation for its gene expression profiling tests in melanoma (搜索) management, with two major studies demonstrating superior predictive capabilities compared to traditional approaches. The developments underscore the growing importance of molecular diagnostics in personalizing cancer care and improving patient outcomes.
Uveal Melanoma Study Shows Superior Survival Prediction
A landmark prospective, multicenter study published in Nature Communications has demonstrated that the combination of Castle Biosciences (搜索)' DecisionDx-UM (搜索) and PRAME (搜索) gene expression analysis significantly outperforms next-generation sequencing (NGS)-based gene mutation analysis in predicting survival outcomes for patients with uveal melanoma (搜索) (UM).
The study, conducted by the Collaborative Ocular Oncology Group (搜索) (COOG) and titled "Early Genetic Evolution of Driver Mutations in Uveal Melanoma (搜索)," analyzed 1,140 primary UM tumors, including 131 small, early-stage tumors. Researchers used NGS to assess seven clusters of recurrent genetic mutations and compared their predictive accuracy with the combined DecisionDx-UM (搜索) + PRAME (搜索) result.
"The DecisionDx-UM (搜索) + PRAME (搜索) combination offers the most comprehensive risk stratification available to guide more informed treatment pathway decisions for patients with UM," said J. William Harbour, M.D., ocular oncologist and professor and chair of the Department of Ophthalmology at UT Southwestern Medical Center (搜索) in Dallas.
Key Study Findings
The research revealed that DecisionDx-UM (搜索) + PRAME (搜索), when used together, provide superior predictions of both metastasis-free survival (MFS) and overall survival (OS) compared to individual gene mutation analysis using NGS. While BAP1 (搜索), SF3B1 (搜索) and EIF1AX (搜索) gene mutations were individually associated with high, medium and low metastatic risk respectively, their ability to predict both MFS and OS became non-significant and redundant when DecisionDx-UM + PRAME were included in multivariate analysis.
The superior performance is attributed to DecisionDx-UM (搜索)'s ability to measure gene activity from both tumor cells and surrounding immune cells, providing a more comprehensive view of the tumor microenvironment. In contrast, targeted NGS analyzes DNA mutations in tumor cells alone.
Expert Panel Endorses DecisionDx-Melanoma for Cutaneous Melanoma
Simultaneously, an independent expert consensus paper published in Dermatology Online Journal has endorsed Castle Biosciences (搜索)' DecisionDx-Melanoma (搜索) test as a best-practice tool for managing patients with cutaneous melanoma (搜索). The paper, titled "31-Gene Expression Profiling for Cutaneous Melanoma: An Expert Consensus Panel," was authored by ten melanoma (搜索) experts from leading academic and clinical institutions.
Drawing on a comprehensive review of 26 published studies encompassing more than 7,500 patients, the panel used a modified Delphi process to reach unanimous agreement on nine consensus statements defining the test's role in risk stratification, sentinel lymph node biopsy (SLNB) decision making and long-term patient management.
Clinical Utility Across Disease Stages
The expert panel concluded that DecisionDx-Melanoma (搜索) demonstrates robust clinical utility and validated performance, supported by high-quality evidence showing accurate and consistent prognostic information for patients with invasive melanoma (搜索). The test can be used across a broad range of tumor stages, with panelists agreeing it should be used in earlier-stage patients to identify those who may benefit from escalated care, guide SLNB decisions in T1b–T3 tumors and inform management for SLNB-negative patients.
Integrating DecisionDx-Melanoma (搜索) results with the American Joint Committee on Cancer 8th Edition (AJCC8) staging significantly enhances prognostic precision, improving risk stratification and survival prediction when used alongside traditional clinicopathologic factors. The panel noted that patients who undergo DecisionDx-Melanoma testing demonstrate improved melanoma (搜索)-specific and overall survival compared to patients not tested, likely reflecting the test's role in supporting more personalized management strategies.
Clinical Impact and Market Adoption
DecisionDx-UM (搜索) has been widely adopted as the standard of care in the United States since 2009 and is included in the American Joint Committee on Cancer (AJCC) Staging Manual and the National Comprehensive Cancer Network (NCCN) Guidelines. The test is supported by more than 25 peer-reviewed publications involving more than 5,000 patients, with nearly 80% of newly diagnosed patients now undergoing DecisionDx-UM testing.
DecisionDx-Melanoma (搜索) has been clinically validated in more than 10,000 patient samples and ordered more than 220,000 times since launch. The test is supported by more than 50 peer-reviewed publications and was developed in collaboration with more than 100 leading U.S. institutions.
"This consensus translates the robust data supporting DecisionDx-Melanoma (搜索) into practical direction for clinicians," said Derek Maetzold, president and chief executive officer of Castle Biosciences (搜索). "The panel's unanimous endorsement of DecisionDx-Melanoma underscores its value in supporting informed, personalized care decisions that may help improve outcomes for patients with melanoma (搜索)."
Castle currently offers three tests for patients with UM – DecisionDx-UM (搜索), DecisionDx-PRAME (搜索) and DecisionDx-UMSeq (搜索), an NGS-based test – all from a single biopsy sample, providing comprehensive molecular insights for precise risk assessment and informed treatment planning.